Genetic Testing Solution Guidelines January 1, 2025

The genetic testing market is growing rapidly, with more than 175,000 tests available today. Our Genetic Testing Management solution addresses the significant complexity that exists in genetic testing by ensuring that medical necessity criteria has been met for tests that may frequently be used inappropriately.

 Genetic Testing Clinical Guidelines for January 1, 2025 Implementation:

• Genetic Testing: Autism Spectrum Disorder / Intellectual Disability Panel Analysis
• Genetic Testing: Bladder Cancer Treatment and Recurrence Algorithmic Tests
• Genetic Testing: BRCA1 and BRCA2 Sequencing and/or Deletion/Duplication Analysis
• Genetic Testing: Breast Cancer Prognostic Algorithmic Tests
• Genetic Testing: Breast Cancer Treatment and Prognostic Algorithmic Tests
• Genetic Testing: Broad Molecular Profiling Panel Tests via Circulating Tumor DNA (ctDNA)
• Genetic Testing: Broad Molecular Profiling Panels for Hematologic Malignancies and Myeloid Malignancy Panels
• Genetic Testing: Chromosomal Microarray Analysis (CMA) for Pregnancy Loss
• Genetic Testing: Chromosomal Microarray Analysis (CMA) for Prenatal Diagnosis
• Genetic Testing: Chromosomal Microarray Analysis for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, or Congenital Anomalies
• Genetic Testing: Colorectal Cancer Prognostic Algorithmic Tests
• Genetic Testing: Comprehensive Arrhythmia and Cardiomyopathy ( Sudden Cardiac or Unexplained Death) Panels
• Genetic Testing: Comprehensive Arrhythmia Panels
• Genetic Testing: Comprehensive Cardiomyopathy Panels
• Genetic Testing: Dilated Cardiomyopathy Panels
• Genetic Testing: Epilepsy Multigene Panel
• Genetic Testing: Evidence Based Lung Cancer Diagnostic Algorithmic Tests
• Genetic Testing: Evidence Based Solid Tumor Minimal Residual Disease (MRD) Testing
• Genetic Testing: Expanded Carrier Screening Panels 
• Genetic Testing: Hereditary Dystonia Multigene Panel
• Genetic Testing: Hereditary GI/Colon Cancer Panel Tests 
• Genetic Testing: Hereditary Polyposis Panels 
• Genetic Testing: Hypertrophic Cardiomyopathy Panels
• Genetic Testing: Long QT Syndrome Panels
• Genetic Testing: Lung Cancer Focused Molecular Profiling Panels
• Genetic Testing: Lung Cancer Focused Panel Tests via Circulating Tumor DNA (ctDNA)
• Genetic Testing: Lynch Syndrome/ Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Testing
• Genetic Testing: Mitochondrial Genome Sequencing, Deletion/ Duplication, and/or Nuclear Genes 
• Genetic Testing: Pan-Cancer Hereditary Cancer Susceptibility Panels 
• Genetic Testing: Pharmacogenetics
• Genetic Testing: Post Heart Transplant Gene Expression Panels for Rejection Risk Via Peripheral Blood
• Genetic Testing: Prenatal Cell-Free DNA Testing
• Genetic Testing: Prostate Cancer Treatment and Prognostic Algorithmic Tests
• Genetic Testing: Rapid Genome Sequencing
• Genetic Testing: Reanalysis of Exome or Genome Sequencing Data
• Genetic Testing: Standard Exome Sequencing
• Genetic Testing: Standard Genome Sequencing
• Genetic Testing: Thyroid Cancer Diagnostic Algorithmic Tests
• Genetic Testing: TPMT and NUDT15 Variant Analysis
• Genetic Testing: Tumor Specific BCR/ABL1 FISH, Qualitative, or Quantitative Tests
• Genetic Testing: Tumor-Type Agnostic Solid Tumor Molecular Profiling Panel Tests
• Genetic Testing: Uveal Melanoma Prognostic Algorithmic Tests